VivoSeq
Other

Smoking Behavior

16

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Smoking Behavior is an emerging landscape with 16 programs across 9 companies. The most active players are Pfizer, Ferring, Axsome Therapeutics, Inc.. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

6/100

Mech. Concentration

22/100

Completion Rate

73/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 1Ferring logo

Ferring

1 program

Phase 1A

Axsome Therapeutics, Inc.

2 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2P

Promius Pharma, LLC

1 program

Phase 2R

Retrophin

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

13

clinical trials

Completed8 · 62%
Terminated2 · 15%
Recruiting2 · 15%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

13 trials

A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior
Recruiting·OOhio State University Comprehensive Cancer Center·N/A·NCT06260683·1,500 enrolled
A Novel Dialectical Behavior Therapy Brief Group Intervention for Cigarette Smoking by Patients With Cancer: An Open Clinical Trial
Recruiting·WWake Forest University Health Sciences·Preclinical·NCT07119489·16 enrolled
A Study in a Human Laboratory Model of Smoking Behavior
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT02641028·71 enrolled
Modeling Stress-precipitated Smoking Behavior for Medication Development
Completed·YYale University·Phase 2·NCT00773357·100 enrolled
Measuring Smoking Behaviors While Using Varenicline
Completed·UUniversity of Pennsylvania·Phase 4·NCT00948155·48 enrolled
AXS-05 Phase II Trial on Smoking Behavior
Completed·—·Phase 2·NCT03471767·58 enrolled
Effects of Menthol in E-cigarettes on Smoking Behaviors
Completed·YYale University·Phase 1·NCT04521647·10 enrolled
The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers
Completed·YYale University·N/A·NCT00633256·20 enrolled
Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00218231·48 enrolled
Effect of Progesterone on Smoking Behavior in Male and Female Smokers
Completed·YYale University·Phase 1·NCT00271206·65 enrolled
Mindfulness Training Plus Oxytocin Effects on Smoking Behavior
Terminated·UUniversity of Southern California·Phase 2/3·NCT03819231·20 enrolled
Neuro Biomarkers of Smoking Behavior
Terminated·UUniversity of Illinois at Chicago·Phase 2·NCT03811951·4 enrolled
Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions
Withdrawn·UUniversity of Florida·Phase 2·NCT02432066

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)